Michael Banks, MD, discusses the risk for cirrhosis regression and liver cancer in patients with HCV-related cirrhosis who have already achieved SVR via DAA treatment.
COPD affects more than 16 million Americans. During his session at the American Lung Association’s LUNGFORCE Expo, Andrew Berman, MD, discussed pharmacologic and nonpharmacologic therapy options for...
Bankole A. Johnson, DSc, MD, of the University of Maryland School of Medicine, discusses a new treatment option on the horizon for alcohol use disorder.
Edmond J. LaVoie, PhD, discusses a new antibiotic that specifically targets variants of the MRSA bacteria, and should be able to circumvent the problem of antibiotic resistance in certain bacterial...
